Capital One, Amex Shares Sink on Trump’s Credit-Card Threat

Summary

---

Bloomberg Intelligence Podcast: Capital One, Amex Shares Sink on Trump’s Credit-Card Threat

Date: January 12, 2026
Hosts: Scarlet Fu and Paul Sweeney (Bloomberg)
Key Experts: Nathan Dean, Poonam Goyal, Sam Fazelli, Geetha Ranganathan

---

Episode Overview

This episode delivers in-depth analysis of pivotal market events and company research through the lens of Bloomberg Intelligence. The hosts and distinguished guests examine the ripple effects of policy proposals, market reactions, company earnings, technological partnerships, and M&A drama, with a sharp focus on the latest headlines impacting financial markets.

Main themes:

• President Trump's announcement to cap credit card interest rates and its impact on financial stocks.
• Lululemon’s turnaround, loyalty initiatives, and leadership transition.
• Nvidia’s $1B collaboration with Eli Lilly for AI-driven drug discovery and Moderna's pandemic-era challenges.
• Paramount vs. Netflix-Warner Brothers bidding war, focusing on deal valuations and legal battles.

---

1. Trump’s Credit Card Rate Cap Proposal and Market Fallout

Guest: Nathan Dean, Senior Policy Analyst, Bloomberg Intelligence
Segment Start: 00:38

Key Discussion Points

• Market Reaction: Shares of Capital One, American Express, and other credit card issuers plunge following Trump's call for a 10% cap on credit card interest rates.
• Legal Realities:
  • Trump’s call is largely symbolic; he lacks the unilateral authority to enact a cap (01:18).
  • Ongoing legislation from Senators Sanders and Hawley seeks a 5-year rate cap but has not gained momentum.
• Probability of Implementation:
  • "We only see a 30% chance of this happening in 2026," notes Dean, emphasizing the practical difficulties (01:44).
  • More likely: Trump leverages regulators (like the CFPB) to pressure companies indirectly.
• Operational Impact:
  • If enacted, banks would implement quickly but would tighten credit, reduce rewards programs, and possibly cut cardholder benefits (02:29).
  • Quote: "A lot of those reward programs...would likely dry up as well, which is not something I think a lot of the American populace would want to see, especially during an election year." - Nathan Dean (02:52)
• Legislative Prospects:
  • Bipartisan interest exists, but bank-friendly committees and election-year politics make passage in 2026 unlikely. Greater risk lies in 2027 (03:41).
  • Quote: "Hearing plus debate, plus negotiations, plus an election year, that just isn’t a timeline to get it done before November 2026." - Nathan Dean (04:14)
• Issuer Impact:
  • Capital One and American Express, with less diversified revenue streams, are more affected than universal banks like JP Morgan (04:57).
  • The issue unites both Republicans and Democrats, keeping policy risk in headlines (05:36).
• Senate Banking Drama:
  • Senator Thom Tillis threatens to block Trump’s Federal Reserve nominees over related disputes, potentially jamming nominations due to the banking committee’s narrow split (06:16).

---

2. Lululemon’s Turnaround: Loyalty, Leadership, and Strategy

Guest: Poonam Goyal, Senior US Commerce & Retail Analyst, Bloomberg Intelligence
Segment Start: 07:17

Key Discussion Points

• Loyalty Program Analysis:
  • Lululemon’s relatively new program offers perks and exclusive access but is not a panacea for deeper issues (07:45).
  • "It’s an added reward for those who have been loyal to the company. But make no mistake, that is not what's going to drive the turnaround." - Poonam Goyal (07:50)
• Recent Performance:
  • Q4 sales on the high end of guidance, yet overall annual sales remain negative, reflecting underlying challenges (09:00).
  • "This doesn’t tell me that the turnaround...is underway and things will begin to improve quarter after quarter." - Poonam Goyal (09:19)
• Macro Trends and Company-Specific Issues:
  • Affluent customer base less pressured by macro conditions.
  • Lack of innovation and weak execution are primary factors behind sales woes—not consumer distress (09:40).
• Leadership Transition:
  • CEO Calvin McDonald exiting; speculation over Jay Nielsen (Ralph Lauren’s ex-CFO) as a successor. Founder Chip Wilson still influential via critique and 9% stock ownership (10:58, 11:14).
  • "As long as they get a product led executive, which he is, Lululemon could be in good hands to continue this turnaround." - Poonam Goyal (11:09)
• Competitive Landscape:
  • Rising threats from brands like Nike, Vuori, Alo, and Athleta mean Lululemon must recapture its product edge.
• Growth Drivers:
  • Product innovation and execution are critical to restoring traffic and growth (12:08).
  • "To see that come back is going to be driven by two things in my mind: One is execution and the other is product." - Poonam Goyal (12:33)

---

3. Nvidia and Eli Lilly: A $1B AI Drug Discovery Partnership

Guest: Sam Fazelli, Director of Research, Bloomberg Intelligence
Segment Start: 13:04

Key Discussion Points

• Headline: Nvidia invests $1 billion with Eli Lilly to develop an AI-powered drug laboratory.
• Purpose of Partnership:
  • Automate and accelerate labor-intensive lab processes and 24/7 experimentation to speed up scientific discovery and time to market (13:41).
  • "At the end of the day, the aim here is to try and get scientific discoveries, translate it to drugs quicker and get them to market quicker." - Sam Fazelli (14:25)
• Industry Impact:
  • Most pharma companies are already engaged in AI initiatives; this partnership underscores the sector-wide push.
  • Example: Google’s DeepMind developing agentic AIs that test hypotheses collaboratively.
  • "Everybody is at this. This is not something specific to Lilly." - Sam Fazelli (14:58)
• Financial Context: $1B is manageable for both Nvidia and Lilly, but headline-grabbing due to their scale.
• Moderna’s Position:
  • Moderna, post-pandemic, faces instability due to declining vaccine sales, patent litigation, and shifting U.S. policy.
  • Moderna’s U.S. covid vaccine sales exceeded expectations, but uncertainty remains (15:55).
  • "There is a constant change in the way the administration in the US...is dealing with vaccination." - Sam Fazelli (16:54)
• Next Growth Catalysts for Vaccine Makers:
  • Companies are leveraging mRNA tech for cancer therapies, aiming to trigger immune responses against cancer cells (18:08).

---

4. Paramount/Skydance and Warner Brothers: M&A Lawsuit and Bidding Drama

Guest: Geetha Ranganathan, Bloomberg Intelligence
Segment Start: 18:55

Key Discussion Points

• Setting the Scene:
  • Paramount embroiled in an escalating contest against Netflix for Warner Brothers’ streaming and studio assets.
  • Lawsuits and proxy threats intensify; described as “somewhat ugly” (19:31).
• Deal Valuation Dispute:
  • Paramount’s offer ($30/share) called “inadequate” by Warner Bros. in light of Netflix’s partly stock/cash proposal (22:11).
  • Key conflict: How much are Warner’s TV networks worth? Paramount argues $0/share (citing Versant’s weak debut); Warner internally estimates $3–$4/share (20:24).
  • "What Paramount is asking in this lawsuit is to really clarify all of these aspects, like what is the stub value...come out in the open." - Geetha Ranganathan (21:31)
• Bid Dynamics:
  • Only 2% of shares tendered, showing shareholders are holding out for a stronger offer.
  • Paramount likely must raise its bid for any hope of success (21:39).
  • "Paramount, I think, has to...raise the offer. Ultimately." - Geetha Ranganathan (22:59)
• Regulatory & Timeline Factors:
  • January 21st is the shareholder tender deadline; it can be extended, but continued back-and-forth adds to deal uncertainty (23:22).
• Potential for Proxy Fight:
  • Possible but likely unproductive; Warner Bros. shareholders support management and believe the networks have value (23:59).
  • "I don't necessarily know that a proxy fight would be productive for Paramount." - Geetha Ranganathan (24:17)

---

Notable Quotes & Memorable Moments

• “We only see a 30% chance of this happening in 2026.” — Nathan Dean on Trump's interest rate cap proposal (01:44)
• “A lot of those reward programs...would likely dry up as well...” — Nathan Dean on effects of capping credit interest rates (02:52)
• “As long as they get a product led executive...Lululemon could be in good hands.” — Poonam Goyal on the CEO search (11:09)
• “The aim here is to try and get scientific discoveries, translate it to drugs quicker and get them to market quicker.” — Sam Fazelli on Nvidia-Eli Lilly partnership (14:25)
• “Everybody is at this. This is not something specific to Lilly.” — Sam Fazelli on industry-wide AI adoption in pharma (14:58)
• “Paramount, I think, has to...raise the offer. Ultimately.” — Geetha Ranganathan on the Warner Bros. bidding war (22:59)

---

Timestamps for Key Segments

• Trump’s Credit Card Rate Proposal: 00:38 – 06:26
• Lululemon Turnaround Discussion: 07:17 – 12:43
• Nvidia/Eli Lilly AI Drug Partnership & Moderna: 13:04 – 18:34
• Paramount vs. Netflix–Warner Bros. Deal: 18:55 – 24:31

---

Tone and Style

• Analytical, high-paced, and sharply critical where warranted.
• Mix of professional insight and conversational rapport between hosts and guests.

---

For listeners wanting clarity on intricate market movements, regulatory drama, and bold M&A showdowns, this episode is a masterclass in rapid, insightful financial commentary.

Transcript

[Alex]

Ditch the complexity. Intuit Enterprise Suite delivers AI native ERP that is intuitive and intelligent.

[Scarlett Fu]

Scale faster with advanced control.

[Alex]

Getting started in days, not months.

[Scarlett Fu]

Learn [e-mail] Enterprise and get the power you need.

[Podcast Host]

Bloomberg Audio Studios Podcasts Radio news. You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10am Eastern on Apple CarPlay and Android Aut Burke Business App Listen on demand wherever you get your podcasts or watch us live on YouTube.

[Scarlett Fu]

I look at the Bloomberg terminal and the top story all morning long has been about shares of Capital One Amex tumbling along with some other banks that issue credit cards following President Trump's announcement that he is calling on these companies to cap interest rates at 10% a year, which could threaten their profits, billions in profits for the industry. Let's bring in now Nathan Dean. Nathan is our senior policy analyst at Bloomberg Intelligence. And Nathan, one thing that we need to make clear, President Trump calling for this is not the same as him actually having authority to do this. Is this something in which he has the authority to call for a cap on interest rates for credit card companies?

[Nathan Dean]

No, it's not. And that should be the first question that these investors look at is how would President Trump implement this? Because look, he said that effective January 20th that there would be a one year cap at 10%. But really there's no way that he can implement this. There has been legislation from Senators Bernie Sanders, the Independent, and obviously Josh Hawley, the Republican to actually put in a cap for five years, but that legislation really hasn't gone anywhere. Now the industry averages around 21% going down to 10%. Obviously you're going to see a significant decline in what the interest would be to these banks and obviously that we're starting to see what the potential of that would be in the stock market. But you know, our note that we put out to clients this morning is said, look, we only see a 30% chance of this happening in 2026. The more likely scenario is that President Trump uses the regulators. Ironically, it would be one of the consumer, the Consumer Financial Prot Bureau, the regulator that they've been moving to get rid of. But they would use the regulators in the bully pulpit to pressure these firms to actually lower interest rates on their own. But absent that, you know, these credit card company banks, they can continue to operate as is.

[Alex]

Let's say this policy actually did go into effect in terms of timeline, how long would it take for some of these companies to actually cap their, their rates?

[Nathan Dean]

So it'd be fairly quickly. I mean, Obviously, it wouldn't be so much an operational standpoint of capping the, the rate at 10%. But the question would be, what are you going to do with the credit risk that of that? Because, you know, a lot of these reward programs, think of those, you know, those fancy lounges at JFK and at DCA and Reagan. You know, a lot of that is paid for by the fact that you have high quality credit and you have low quality credit consumers as part of this. And so one of the, the note that we put out in the morning this morning showed that if you were to curve the tail this down to 10%, banks would be a little bit more choosy about who they are offering credit to. You would actually see a decline in terms of the number of users of credit cards, which ultimately could have a small impact on Visa and MasterCard and forth. But a lot of those reward programs that people enjoy would likely dry up as well, which is not something that I think a lot of the American populace would want to see, especially during an election year.

[Scarlett Fu]

Yeah, especially since they already paid the $895 annual fee and want to get something for it. Nathan, you mentioned that there has been legislation proposed to target these interest rate levels at these credit card issuers. Now that President Trump has made this something of a rallying cry, do you think that that legislation will have more of a chance of getting anywhere?

[Nathan Dean]

So, you know, normally I would say More so in 2027, less so in 2026. The reason being is in an election year, and look what President Trump proposed, there are a lot of Democrats on Capitol Hill that actually would be in favor of this. You want to cap credit card interest rates at 10%, you could probably get a significant number of Democrats to say, yeah, we're on board. But the problem here for the president is, is that there's probably an unspoken Republican populace. And I'm specifically looking at the House Financial Services Committee and the Senate Banking Committee at the moment that have bank allies that are completely against this move. And so what I is is that if President Trump says that we want to push this legislation, and if the folks on the Senate side say, look, we want to work on this legislation, the most step that you would have is have a hearing to talk about that legislation. So hearing plus debate, plus negotiations, plus an election year, that just isn't a timeline to get it done before November 2026. I think the real risk is if you see this in 2027, but by then, you know, this issue may be moot and off The President's mindset.

[Alex]

Nathan, I'm just looking at the market reaction here from some of these credit card issuers, Capital One, American Express, just their share prices falling more substantially than some of the banks like JP Morgan. How much more significant would the impact be on these credit card issuers versus say the big banks that are also issuing credit cards?

[Nathan Dean]

Well, it's a story of diversification in revenue. I mean, the Capital One, the American Express, you know, the credit card issuers, you know, it certainly drives higher bulk of their revenue than if you think of like the JP Morgan's of Bank Americas, which have investment banking, commercial banking and other types of operations. And that's part of the reason why policy risk is hitting these companies more so than others is because, you know, if you look at Capital One and American Express in particular, you know, there's less of a deregulatory story to tell than what you're seeing in the bank big banks at the moment. You know, when they say the deregulation for the banking industry is coming, they're most likely saying deregulation is coming for those big banks in terms of capital requirements of returning towards those banks. You know, Capital One and America Express have a different type of operating model and as a result, this issue in particular is more exposed. But I would just say is, is that risk for these companies continue because it's a Republican issue, it's a Democratic issue and as a result, this bipartisan issue is going to continue in the headlines.

[Scarlett Fu]

Nathan, before we let you go, just very quickly here, Senator Thom Tillis pushing back against this idea of the president targeting Jay Powell and the Federal Reserve. He says he will oppose any of Fed's, Trump's, Fed nominees, including the chair, until this issue is resolved. With regards to the criminal indictment that's been threatened against the Fed, you think that will have an impact on the president? On the White House?

[Nathan Dean]

It will if Senator Thomas falls through with it. And it will depending on what his definition of resolve is. Because the Senate banking committee is 13 to 11 and he can effectively jam that nomination up.

[Scarlett Fu]

Stay with us. More from Bloomberg Intelligence coming up after this. Stop struggling with complex, costly ERP systems. Introducing Intuit Enterprise Suite, the AI native ERP that adapts with your business. Get enterprise grade power made, intuitive, intelligent, adaptive and ready for what's next. It streamlines complex financial management, automates workflows and unifies all your entities. It's simple to access and quick to adopt, helping you get going in days, not months. Get the power you need without the complexity. Learn [e-mail] Enterprise now.

[Podcast Host]

You'Re listening to the Bloomberg Intelligence podcast. Catch us live weekdays at 10am Eastern on Apple CarPlay and Android Auto with the Bloomberg business app Listen on demand wherever you get your podcasts or watch us live on YouTube.

[Alex]

Scarlett it looks like we have Lululemon rising as holiday sales show signs of a rebound. To explain that, we have Poonam Goyal. She is senior US Commerce and Retail Analyst at Bloomberg Intelligence. Poonam I' a big Lululemon shopper. So it was only recently that I discovered that they actually have a membership which is really interesting. I can't help but wonder what is this loyalty program? How does it influence repeat purchase behavior and margins for the company?

[Poonam Goyal]

Yeah, so the loyalty program is not something that Lululemon has had for a long, long time. But it does help. Just like with any other loyalty program. You know, it gives you perks, you have access to to Lululemon merchandise, you have access to Lululemon events, etc. And it does bring the member who enjoys the Lululemon experience to keep coming back. It's an added reward for those who have been loyal to the company. But make no mistake, that is not what's going to drive the turnaround. Their turnaround needs a lot more than that.

[Scarlett Fu]

Yeah, I mean loyalty programs are something that most brands have and Lululemon has some more structural issues. Let me just jump in here because we have a headline showing that Al when it rose as much as 1.7%, it actually surpassed $4 trillion in market value. This comes after Apple reportedly has chosen Alphabet's Gemini to run its AI powered Siri this year. That's according to cnbc. Put on. Let me get back to you here. When it comes to Lululemon, separate from the loyalty program, Lulu has preannounced fourth quarter sales and it comes in at the higher end of its guidance. This is kind of surprising because Lululemon has struggled to connect with shoppers the last couple of quarters.

[Poonam Goyal]

Yes, you can say that it's surprising, but at the end of the day, the sales are still down. The estimate was for sales to be down negative 1 to 3%. So maybe you're close to minus 1. That's still not where we expect Lululemon to be. This doesn't tell me that the turnaround is, you know, has started and is underway and things will begin to improve quarter after quarter. I think it's good, but I need a lot more to be confident that the turnaround will begin to take place.

[Alex]

What are Some of the macroeconomic trend trends that are driving Lululemon's customer base. Is it inflation? Is it just an overall change in discretionary spending patterns? What is it?

[Poonam Goyal]

Yeah, so the macro economy has been, you know, good and bad. The luxury consumer has been doing well. Lululemon, you could argue, sits in the affluent space of activewear. But that said, it's not that the customer is pressured and that's why their sales have fallen. It is that they have lacked innovation and execution has been weak. So the key here is a company specific issue that they need to resolve and they are working towards it. We will be getting a new CEO hopefully at some point in 2026. And it'll really be then where we can see who comes in. What's the strategy and how does Lululemon re engage its core customer that probably still loves the brand but just hasn't found enough new to keep going back and back?

[Scarlett Fu]

Yeah, absolutely. I think about the competitors that Lululemon faces in this space. It ranges from dory to all the other big names out there, including Nike, which offers perhaps similar athleisure wear, but at a lower price point too when it comes to this new CEO. Calvin McDonald, the current CEO is set to step down at the end of January. And I know Elliott has been a big player in pushing for Jane Nielsen, the former CFO at Ralph Lauren to represent place him. What's the latest on that? Do we presume that Jay Nielsen is going to be the next CEO?

[Poonam Goyal]

I mean, we don't know yet. Right. So it's definitely one of the contenders and could be. And I think as long as they get a product led executive, which he is, Lululemon could be in good hands to continue this turnaround.

[Scarlett Fu]

So founder Chip Wilson is also kind of involved here. That's another name that we haven't heard from in a while. He founded the company. He no longer sits on the but he still owns about 9% of the stock. How much do you pay attention to what he says? Who now we.

[Poonam Goyal]

We definitely look at it. Look, what he says is important. He founded the company. The company was grounded on innovation on product. And I think he makes fair points that the company needs to kind of really re engage the customer and go back to its roots, which is are you still ahead of the competition? Like, you know, you mentioned earlier, competition has increased and it has, but competition was always there. But where is Lululemon ahead of it? Can you get similar athleisure pants or leggings at Viori or at Alo or Athleta, how does Lululemon stand out today? And that's the big question that they need to answer.

[Alex]

Poonam, what might be the next drivers of revenue growth for Lululemon?

[Poonam Goyal]

It's all product. I think they are engaging in new product innovation. And as we see that rollout and see that resonate, we think that is what will drive back traffic. Lululemon was a store in the mall that for me was like Apple, right? No matter how dead the mall was, the store had people in it. Today when I walk in, that is not the case. So to see that come back is going to be driven by two things in my mind. One is execution and the other is product.

[Scarlett Fu]

Stay with us. More from Bloomberg Intelligence coming up after this.

[Podcast Host]

You're listening to the Bloomberg Intelligence podcast. Catch us live weekdays at 10am Eastern on Apple CarPlay and Android Auto with the Bloomberg Business app. Listen on demand wherever you get your podcasts or watch us live on YouTube.

[Scarlett Fu]

I'm Scarlet Fu and we've got some news about the top AI company, kind of the poster child for AI, Nvidia teaming up with the top pharma name, Eli Lilly. The two are going to work together with Nvidia investing $1 billion into an AI drug laboratory. What does that mean? What are they going to use it for? Let's bring in Sam Fazelli. He is Bloomberg Intelligence's director of research for global industries and senior pharmaceuticals analyst. He always gives us his read on the biotech sector. Sam, good to speak with you. How do you make sense of this headline, Nvidia investing $1 billion in an AI drug lab with Eli Lilly Garlic.

[Sam Fazelli]

Very nice to talk to you again today. Well, look, I think these are the trillion dollar club getting together. $1 billion is probably a drop in the ocean for both of them. It's over five years. And what I think the aim of this at the end of the day is to try and automate and speed up as much of the partly the drudgery of doing lab work because lab work just like as if you were a doctor in a clinic clinical setting, you need to take a lot of notes, a lot of details. But at the same time I think they're investing in what appears to be automating 24. Seven experiments, things that human beings just can't do. And, and I know having been a scientist that sometimes your life is on hold because you have to go back and deal with your experiments, your cells or whatever it is that you're running. And so a lot of these things I think could speed up and also make the life of the scientists a little bit easier. At the end of the day though, I think the aim here is to try and get scientific discoveries, translate it to drugs quicker and get them to market quicker.

[Alex]

Sam, what does this mean for Eli Lilly's rivals? Do you expect that we'll see some of its competitors also ramp up their AI endeavors given its partnership with the company like Nvidia?

[Sam Fazelli]

Well, a lot of pretty much all pharma companies. And I just want to point you to a recent survey that Bloomberg Intelligence has done that looked at 10 different industries, one of which being the pharmaceutical industry. Asked executives, what are you doing with this? What are you trying to get to? What is the aim at the end? Everybody is at this. This is not something specific to Lilly. And you know, Google, for example, has, has through DeepMind, has created an agentic AI called Google Scientist. It's like I think four agents or five agents who interact with each other and check each other's hypothesis. So a lot of this is going on in all companies. But of course here we have Lilly, one of the richest pharma companies around in terms of the amount of cash flow that it's got, really being able to spend the money without really impacting its balance sheet and cash flow. And I'm pretty sure everybody's at this, but clearly this is the news du jour, if you like.

[Scarlett Fu]

Absolutely. Like you said, it's a drop in the bucket for both of these companies. But when you have a number like $1 billion and these big brand names, it gets people's attention. What also gets my attention, Sam, is Moderna. Moderna, obviously one of the vaccine makers during the pandemic. But it's had a rough go at it recently because it's so dependent on these vaccines. And we have an administration that is kind of anti vaccine right now. Yet Moderna preannounced at the J.P. morgan Health Care Conference that its U.S. covid business did better than expected. Is Moderna starting to stabilize?

[Sam Fazelli]

Well, one would hope so. They've stuck with their aim of growing 2026 by 10%. But you know, if you look back at the beginning of the year, where the company in 2025 started with guidance and where we ended up, we are a good 5, $600 million short of what the hope was at the beginning of the year. So everybody I think, knows that this is a very difficult market to call for exactly the reasons you just highlighted. There is a constant change in the way that the administration in the US and not just the US Elsewhere is also dealing with vaccination, particularly in the COVID side of things. Other vaccinations are still pretty much well settled and at least outside the US the problem also that Moderna is going to face or has facing is that there are lots of people. There's, I think my patent colleagues say there are at least 20 various directions of legal cases or trials going on. Different groups saying you're infringing my patents or you infringe my patents and you need to, because there was billions and billions of dollars of revenues. So some of that is coming potentially in the March time frame for Eli Lee against a trial coming up against Arbutus, another company that's listed in the US So some of that is, I think, something that might keep people from getting too excited about Moderna's guidance today.

[Alex]

Sam, very quickly, obviously the end of the pandemic has made it hard for pharmaceutical companies, U.S. officials curbing the people who are eligible for them. What then are the next growth catalysts for vaccine makers?

[Sam Fazelli]

Oh, well, I think a lot of these companies are trying to use the technology, which is the MRNA technology, at least those with an MRNA technology who develop cancer therapies. Remember, at the end of the day what you're trying to do is get an immune response, which is what vaccines do against something relatively foreign. In infectious diseases, it's a virus. In cancer, you're trying to get cancer cells killed and recognized by the immune system. That's where these guys are going.

[Scarlett Fu]

Stay with us. More from Bloomberg Intelligence coming up after this.

[Podcast Host]

You're listening to the Bloomberg Intelligence podcast. Catch us live weekdays at 10am Eastern on Apple CarPlay and Android Auto with the Bloomberg business app Listen on demand wherever you get your podcasts or watch us live on YouTube.

[John]

You know the Bonnie Raitt song I don't. I can't make you love me.

[Alex]

You have to sing it for us.

[John]

Well, no, I'll spare you that. I feel like that's how Paramount Skydance is feeling. This drama just is never ending. They made some new moves to try and get Warner Brothers to dump Netflix and choose them. And Geetha Ranganathan with Bloomberg Intelligence is here. She's gonna try to sort this out for us. Do I sense desperation on the part of Paramount Skydance? It seems it's not the cost of getting Warner Brothers, but the cost of not getting Warner Brothers. That's the big issue.

[Alex]

Yeah, absolutely, John, you're absolutely right. And this is the truth. This is the hard hitting truth for really all of these legacy media Companies, right. How much are they going to lose out if Netflix actually does go, you know, end up winning this whole bidding war for Warner Brothers? And that's really what we see today from Paramount, basically, you know, the whole letter to shareholders as well as the legal, the lawsuit that they've, that they just filed, basically threatening a proxy fight. So things are kind of getting very, very interesting somewhat, I would say even somewhat ugly.

Ethan, I'm just reading this report. It says that the lawsuit is aiming to force out into the open more details about Netflix's takeover agreement. What exactly is this lawsuit alleging? What is it supposed to do here? And is it just posturing, perhaps?

It's a. Yeah, I think it's all of the above, Alex. So really, what, what we're, you know, so we have one number which is there for the streaming and the studio assets. Remember, the whole Warner Brothers transaction is about two different units, really. So one is the streaming in the studio assets. And for that we already have a deal from Netflix, which is for about $28 a share. Now, what is a share? What is really, so to speak, in the air, so to speak, is the remaining part of the business, which is the TV network business, the what is called the global networks or Discovery Global. And here is where, you know, there is a lot of questions about where exactly that should be valued. So Paramount pretty much has come out and said that it should be valued at $0 a share. And they base their argument on the recent trading debut of Versant, which is the cable network spinoff from Comcast, which has fared really, really poorly in its, in its first week, the stock off almost 30%. And so that, you know, Paramount kind of using that as their defense for valuing these Warner Brothers networks at next to nothing. Warner Brothers, on the other hand, obviously internally has a number for those networks. They, you know, according to reports, think it's worth about $3 to $4 a share. So that's really where a lot of this discrepancy is kind of stemming from. And what Paramount is asking in this lawsuit is to really clarify all of these aspects, like what is the stub value, what is, you know, what financial details in the Netflix deal and what is the risk adjusted uncertainty that Warner Brothers is ascribing to the $30 offer from Paramount? So they say they're really asking WBD to kind of spell it all out and come out in the open.

[John]

So I mean, are they doing this on the cheap? Why not just pony up more money? Paramount.

[Alex]

Yeah. So, you know, right now their offer is obviously $30 a share, which Warner Brothers has called inadequate and inferior to the Netflix deal. Of course, you know, Paramount keeps arguing that their offer is all cash versus Netflix, which is, you know, partly cash and partly stock. And, you know, the stock is obviously has been really like it's been going down in value. So again, that part of it is a little bit of a question mark. But really this is, you know, I think ultimately what's going to happen is they are going to have to sweeten the deal. There is no doubt about that, because we haven't seen a whole lot of action in terms of the Warner Brothers shareholders actually tendering their shares. And that's really what it's going to come down to. So only about 2% of the shares have been tendered, which means that the shareholders are really waiting for a higher bid. So Paramount, I think, has to, you know, raise the offer. Ultimately.

Keith kind of feels like this bidding war has no end in sight. We get some new escalation every day. From a regulatory perspective, perhaps. Perhaps. Is there any limitation for how much longer this be could. Can go on and what does it do for the terms of the deal for, you know, if it keeps dragging on much longer?

Yeah, it's definitely not. Not good for anybody. Right. It just kind of keeps adding to the uncertainty here. But in terms of the dates and what we know so far, January 21st so far, is the deadline that Paramount has set for the Warner Brothers Discovery shareholders to tender their shares. Now, they can very well come back and extend that deadline or they may not. They may choose to walk away from the deal, or they may choose to raise the offer. So again, a lot up in the air at this point. Just, we're kind of playing a waiting game here. Alex.

[John]

What a proxy fight, what would that look like?

[Alex]

That is going to be really ugly. And I don't think, obviously that kind of changes a lot of things. I think the Warner Brothers Discovery shareholders, however, do believe that the board, the management, is doing the right thing. I think they do believe that the Netflix offer is actually superior. And I think that they do believe that the TV networks are actually worth something, something much more than what Paramount is suggesting. So again, I don't necessarily know that a proxy fight would be productive for Paramount.

[Podcast Host]

This is the Bloomberg Intelligence podcast, available on Apple, Spotify and anywhere else you get. Your podcasts listen live each weekday 10am to noon eastern on bloomberg.com the iHeartRadio app, TuneIn, and the Bloomberg Business app. You can also watch us live Every weekday on YouTube and always on the Bloomberg terminal.